Exchange: NYSE·Updated 07:30 PM EST
NUVB logo

NUVB Nuvation Bio Inc - Ordinary Shares - Class A

$3.80
$0.01
(0.26%)
Today
Closed $3.80
$0.00
(0.00%)
After Hours
Reported EarningsNov 4
Mkt Cap$1.35B
Vol6.85M

About NUVB

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.
28

Bearish Sentiment

How do you feel about NUVB?

copywrites
$NUVB Part 1: KEY MANAGEMENT MESSAGES 1. Market leadership - More new patient starts than all competitors combined - Leader in total active patients across all lines (incl. long-term patients on older TKIs) and in first line - First-line share of new starts currently >60% - Launch ~2x faster than earlier-generation ROS1 TKIs (in January: "~6x" – different comparator) 2. Q3 market decline - Overall ROS1 TKI market -15% in new starts, confirmed by IQVIA AND ROS1 testing alerts from partner labs - Management views it as a fluctuation, not a trend 3. Duration of therapy - Real-world duration of therapy consistent with trial data (TRUST) 4. Competition - No material impact of new entrants on active patient share - New competitor used mainly in later lines, no off-label use in TKI-naive patients - IBTROZI the only brain-penetrant option without a CNS warning in its label
1
14
AProst
$NUVB People are smoking the hash pipe if they don’t think that was an overwhelmingly successful Q report and follow up conference call. The only (minor) observation I have is Hung’s voice did sound tired. Other than that, they hit it out of the park. My opinion only.
11
Shagg85
$NUVB amazing data and we still drop like every single piece of good news we get. These market makers are specifically punishing Dr Hung and Nuvation bio. The illegal corruption going on here is unbelievable.
9
njbugatti
$NUVB per LinkedIn page, NUVB released new data at ESMO this past weekend. I guess we will get info in earnings release.
1
6
Shagg85
$NUVB reversal has happened in my opinion. And i believe we are looking at a massive move up shortly.
5
copywrites
$NUVB Safusidenib – SNO 2026 (Phase 2 J201 update) • 27 pts (Japan), grade 2 IDH1-mutant glioma, RT/chemo-naive • Efficacy cutoff 03/2024 – no new headline numbers vs. July topline • ORR 51.9% (central): 0 CR, 4 PR, 10 minor responses • PFS rate 87.9% at 24 mo, 79.1% at 36 mo; median PFS + DOR not reached • Median time to response 14.1 mo; median best tumor shrinkage −27% • Most pts on treatment >3 years (median exposure 46.7 mo) • AEs: alopecia 59%, arthralgia 56%, skin hyperpigmentation 52%, ALT↑ 41% (grade ≥3: 7%) • Interruptions 74%, dose reductions 37%, discontinuations 11% (2x liver toxicity, resolved) • Other 3 posters trial designs only (SIGMA, G209, grade 3 oligo) • Takeaway: durable activity confirmed, but hair/skin AEs a drawback vs. vorasidenib
8
Shagg85
$NUVB well today wasn’t the best. But looking at the whole market. I think we ended up pretty well today. Is this finally the reversal Nuvation bio has earned over and over again ? Quarter over quarter revenue growth beating estimates every quarter amazing data from our phase 2 safusidenib which holds fast track designation. I hope the market makers are finally done manipulating and playing games. You are NOT getting our shares, so let this company fly like it should!!!! Have a good weekend everyone cheers 🍻
6
Mikebaz
$NUVB we have updates coming on nov. 13th . and beyond if you believe in this company block out all the noise and relax NUVB day in the sun is coming and it will be spectacular !!!!!!!!!!!
8
Bio_Invest101
$NUVB Latest SI reduced 1 million shares with 12.5 DTC. Bears and shorts are becoming reckless in betting against Dr Hung with his own 60 million shares holdings. His NUVB portfolio has lost over $300 million dollars on paper from $9.75 high in 2026. Don’t you think he has pride and eager to prove doubters wrong? Read the latest corp deck. Not many small biotech has Our strong fundamentals. Have some Patience and faith. Better time ahead and 2027 will be a great year.
7
n9zro
$NUVB I put 90 % of my eggs in 1 basket..my bad..now I have to hold and lock up my money for like a year before this recovers (my opinion) or sell and lose upwards up 15 grand...this sucks...again my bad..what makes this more painful is I had a very large position in XERS which I reduced some months ago to shift money into NUVB...again my bad decision...look at XERS last few days...they hit a home run..I still had some money in XERS so I did make some money but cashed out too soon...I do alot of research but I got shaken out of XERS too soon and widh O had bailed out on NUVB but I didn’t so now I m in a big hole..my bad...just venting my frustration at myself..I guess if every trade I made was perfect I d be a millionaire...I still have a one year return of around 130 %...so I ll count myself fortunate...
7
Bio_Invest101
$NUVB my overnight thoughts on the ER below. Regards to Ibtrozi sales Dr Hung and the team feel strongly the lack of better understanding by the street in 50-month DOR in the 1L setting Plus the serious issue JIDEYTRO has shown on 2L… They’re not shy away from Q to Q lumpiness. even big “ALK scripts, they varied as much in general. Just recently, I believe that one of the quarters recently showed a 50% reduction in ALK scripts in the quarter” And this happened often to rare CNS drug early commercialization. Regards to Safu, they believe no third party other than the current leader Varo will be competing in IDH1 Glioma field. And they confirmed that the 2 ph2 Safu trials could provide data readout in 2027. Overall I don’t think there’s too much concern in Ibtrozi taking market shares slowly but surely especially in 1L. JIDEYTRO Is a recognized competitor but waiting in line. I am happy to hear the fast Safu developments & 2027 is not far away. Traders will trade. BLTA
7
ak123456790
$NUVB Bringing the SLS profits here ! Next year it will explode ! Dirty cheap , thank you shorties for taking it down , plenty of cash to invest at these levels !
6
Bio_Invest101
$NUVB missed the last 1-2 minutes…was the one dropped off a bit earlier? Anyway a very positive, clean, clear analysis call with Jefferies. sorry I didn’t hear the discussion if any about the details of the 5 EU countries expanded into Safu trials but 2 Safu trials will have data readout in 2nd half 2027. Hung will take those data to FDA. This timeline is solid from 2-trial data And the confidence in Ibtrozi data and 1L Superiority is obvious over GSK/ZIde RD Day early 2027 will cover DDC program then some Traders will trade. OGs shall stay calm knowing the man in charge doing exactly what he has planned. It just takes some time. Know what you own.
6
Spartucus
$NUVB Breakthrough drugs don’t always translate into blockbuster commercial success. Nuvation has consistently referenced a ~3,000 annual ROS1 patient opportunity. At 60% market share, that implies 1,800 new patients annually. But that doesn’t seem realistic. I believe the commercially addressable market may be closer to 1,500 patients annually, implying ~900 new starts at 60% share. Q3 delivered approximately 160 new starts, or a 640 annualized pace. That’s a significant gap. IBTROZI is an exceptional drug, but the real question isn’t whether Nuvation can capture 60% market share. It’s whether the actual treated market is large enough to support blockbuster expectations and drive revenue and profit. Long treatment duration helps, but patient volume ultimately matters most! The biggest risk may not be competition or drug efficacy. It may be that investors are valuing a 3,000-patient opportunity when the realistically accessible market is substantially smaller.
6
marti837
$NUVB Nuvation Bio has rapidly established IBTROZI as the ROS1 market leader, capturing approximately 60% of new patient starts and leading in total active patients. In Q3 2026, the company generated $45 million in total revenue, including $27.5 million in IBTROZI net product revenue, representing 18% quarter-over-quarter growth. With $663.4 million in cash and a median duration of response of 49.7 months in treatment-naïve patients, Nuvation Bio is well-positioned to drive sustained growth and advance its promising pipeline.
6
BigHig711
$NUVB beat the street and acnew 5 star analyst rating tonight of $12.  That could only mean one thing in this game of manipulation. The stock goes down after hours. Hmmmm
6
ak123456790
$NUVB Hung is expanding to Europe, in order to get later the European approval easier without doing an extra phase which will take time! He knows that the drug works, so he is trying not to loose time! Company has plenty of cash, so he is not worried! Probably he knows Ibtrozi is going very good in sales, maybe a good sign for next week!
6
Rayvio_News_Filter
$NUVB 🏥 Nuvation Bio Inc. announced new long-term follow-up data from the Phase 2 J201 study of safusidenib in IDH1-mutant glioma, showing an 81.5% confirmed clinical benefit rate and a 27.2% median target lesion reduction with nearly 40 months of follow-up. Selected from hundreds of headlines
5
Belisimo
$NUVB Possibility of a European partnership with Safusidenib? Similar to their Eisai deal?
5
Belisimo
$NUVB I feel any day now we'll get the UK Mhra go ahead which will be our next catalyst by years end.
4

Advertisement|Remove ads.